These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20829243)

  • 21. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study.
    Paolicelli D; Manni A; Iaffaldano A; Di Lecce V; D'Onghia M; Iaffaldano P; Trojano M
    Eur J Clin Pharmacol; 2016 Aug; 72(8):1025-9. PubMed ID: 27251359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together.
    Messori A; Fadda V; Maratea D; Trippoli S
    J Neurol Sci; 2014 Dec; 347(1-2):408-10. PubMed ID: 25455308
    [No Abstract]   [Full Text] [Related]  

  • 26. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.
    Yildiz M; Tettenborn B; Putzki N
    Eur Neurol; 2011; 65(4):231-2. PubMed ID: 21454981
    [No Abstract]   [Full Text] [Related]  

  • 28. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
    Gonsette RE; Sindic C; D'hooghe MB; De Deyn PP; Medaer R; Michotte A; Seeldrayers P; Guillaume D;
    Mult Scler; 2010 Apr; 16(4):455-62. PubMed ID: 20200198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis.
    Milanese C; La Mantia L; Salmaggi A; Caputo D
    J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):413-4. PubMed ID: 11181879
    [No Abstract]   [Full Text] [Related]  

  • 31. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ
    J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories.
    Shahkarami MA; Vaziri B; Salami S; Harandi AA; Oger J
    J Immunol Methods; 2013 Feb; 388(1-2):46-8. PubMed ID: 23220098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A
    Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
    Polman C; Schellekens H; Killestein J
    Mult Scler; 2006 Jun; 12(3):245-6. PubMed ID: 16764335
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
    Koch M; Mostert J; De Keyser J; Tremlett H; Filippini G
    Ann Neurol; 2008 Jan; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multiple sclerosis. Therapeutic nihilism is the wrong approach here].
    Voltz R; Goebels N; Jarius S; Hohlfeld R
    MMW Fortschr Med; 2002 May; Suppl 2():52-7. PubMed ID: 12070851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.